Globeflex Capital L P Purchases New Stake in Medpace Holdings, Inc. $MEDP

Globeflex Capital L P acquired a new position in Medpace Holdings, Inc. (NASDAQ:MEDP) in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 10,963 shares of the company’s stock, valued at approximately $5,806,000.

A number of other institutional investors have also recently bought and sold shares of the business. Johnson Financial Group Inc. purchased a new position in Medpace during the 2nd quarter valued at about $27,000. Geneos Wealth Management Inc. lifted its position in shares of Medpace by 64.9% in the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after purchasing an additional 37 shares in the last quarter. Elyxium Wealth LLC purchased a new stake in shares of Medpace in the fourth quarter worth approximately $30,000. Allied Private Wealth LLC acquired a new stake in shares of Medpace during the second quarter worth approximately $31,000. Finally, Kilter Group LLC acquired a new stake in shares of Medpace during the second quarter worth approximately $31,000. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on MEDP. Jefferies Financial Group lowered shares of Medpace from a “buy” rating to a “hold” rating and upped their price objective for the company from $490.00 to $515.00 in a research note on Tuesday, July 7th. Deutsche Bank Aktiengesellschaft restated a “hold” rating and set a $535.00 price target on shares of Medpace in a report on Thursday, July 23rd. Truist Financial upped their price target on shares of Medpace from $462.00 to $609.00 and gave the stock a “hold” rating in a research note on Friday, July 24th. Robert W. Baird increased their price objective on Medpace from $547.00 to $624.00 and gave the stock a “neutral” rating in a report on Friday, July 24th. Finally, Mizuho lifted their price objective on Medpace from $586.00 to $665.00 and gave the company an “outperform” rating in a research report on Friday, July 24th. Three equities research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company’s stock. According to MarketBeat, Medpace currently has a consensus rating of “Hold” and an average price target of $584.18.

Insider Buying and Selling at Medpace

In related news, CEO August J. Troendle sold 27,174 shares of the stock in a transaction that occurred on Thursday, August 20th. The stock was sold at an average price of $618.79, for a total transaction of $16,814,999.46. Following the completion of the sale, the chief executive officer owned 561,195 shares in the company, valued at $347,261,854.05. This represents a 4.62% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, General Counsel Stephen P. Ewald sold 16,349 shares of the firm’s stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $450.00, for a total value of $7,357,050.00. Following the completion of the sale, the general counsel directly owned 20,343 shares in the company, valued at $9,154,350. This trade represents a 44.56% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 122,261 shares of company stock worth $71,729,129 in the last ninety days. 20.50% of the stock is owned by insiders.

Medpace Price Performance

NASDAQ MEDP opened at $620.75 on Monday. Medpace Holdings, Inc. has a fifty-two week low of $373.00 and a fifty-two week high of $677.90. The stock’s 50-day moving average is $550.16 and its two-hundred day moving average is $492.03. The firm has a market cap of $17.33 billion, a P/E ratio of 36.39, a price-to-earnings-growth ratio of 2.77 and a beta of 1.15.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, beating analysts’ consensus estimates of $3.98 by $0.27. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The business had revenue of $707.33 million for the quarter, compared to analyst estimates of $689.51 million. During the same quarter in the prior year, the firm posted $3.10 EPS. The firm’s revenue for the quarter was up 17.2% on a year-over-year basis. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, equities analysts expect that Medpace Holdings, Inc. will post 17.54 EPS for the current year.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.